Gut Metabolite Desaminotyrosine Prevents Transplant Complications While Fighting Cancer

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a life-saving treatment for blood cancers, but up to 50% of patients develop graft-versus-host disease (GvHD), where donor immune cells attack the recipient's organs. This study reveals that desaminotyrosine (DAT), a metabolite produced when gut bacteria break down dietary flavonoids, can prevent this complication while preserving the transplant's cancer-fighting effects.

Researchers analyzed 857 patient samples and found that higher DAT levels correlated with significantly improved overall survival and reduced relapse rates. In preclinical mouse models, synthetic DAT treatment prevented GvHD by protecting the intestinal barrier and promoting tissue regeneration. Remarkably, DAT's protective effects persisted even when broad-spectrum antibiotics disrupted the gut microbiome.

Mechanistically, DAT activates intestinal stem cells through the mTORC1 pathway while engaging the STING immune receptor to maintain cellular health under stress. This dual action promotes tissue repair without triggering harmful inflammatory responses. Additionally, DAT can shift T cells toward an effector phenotype that enhances graft-versus-leukemia responses, the beneficial aspect of transplant immunity that eliminates residual cancer cells.

The findings suggest DAT could be developed as a precision microbiome-based therapy. Since DAT is produced from common dietary flavonoids found in fruits and vegetables, this research also highlights how diet and gut bacteria interactions influence transplant outcomes. The compound's ability to work independently of the microbiome makes it particularly attractive for clinical development, as transplant patients often receive antibiotics that disrupt beneficial bacteria.

While promising, this research was conducted primarily in mouse models, and human clinical trials will be needed to confirm therapeutic efficacy and optimal dosing strategies.